Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 314.17 g/mol |
|---|---|
| Molecular Formula | C9H17Cl2N5O3 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 313.0708448 g/mol |
| Monoisotopic Mass | 313.0708448 g/mol |
| Topological Polar Surface Area | 132 A^2 |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 405 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, is approved by the U.S. Food and Drug Administration (USFDA).
Lead Product(s): Sapropterin Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Sapropterin Dihydrochloride-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2021
Lead Product(s) : Sapropterin Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, is approved by the U.S. Food and Drug Administration (USFD...
Product Name : Sapropterin Dihydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2021
Details:
The launch of generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating the commitment to bring affordable generic medicines to market for patients. Dr. Reddy’s Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.
Lead Product(s): Sapropterin Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Sapropterin Dihydrochloride-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2020
Lead Product(s) : Sapropterin Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating the commitment to bring affordable generic medicines to market for patients. Dr. Reddy’s Sapropterin Dihydrochloride Tablets, 100 mg are available in bottl...
Product Name : Sapropterin Dihydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2020
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The proposed merger involves Sapropterin Dihydrochloride to target Phenylalanine-4-hydroxylase, addressing PHENYLKETONURIA.
Lead Product(s): Sapropterin Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: RLF-OD032
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Relief Therapeutics | NeuroX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sapropterin Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Relief Therapeutics | NeuroX
Deal Size : Undisclosed
Deal Type : Merger
Relief Therapeutics, NeuroX Merge to Create MindMaze Therapeutics
Details : The proposed merger involves Sapropterin Dihydrochloride to target Phenylalanine-4-hydroxylase, addressing PHENYLKETONURIA.
Product Name : RLF-OD032
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sapropterin HCl, a miscellaneous product, shows promise in treating PAH, with a key focus on Phenylketonuria (PKU).
Lead Product(s): Sapropterin Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sapropterin Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Therapeutics Reports Positive Results from RLF-OD032 Study
Details : Sapropterin HCl, a miscellaneous product, shows promise in treating PAH, with a key focus on Phenylketonuria (PKU).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RLF-OD032 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): RLF-OD032,Sapropterin Hydrochloride
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RLF-OD032,Sapropterin Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed
Details : RLF-OD032 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RLF-OD032 (sapropterin dihydrochloride) is a PAH agonist small molecule drug candidate which is being evaluated for the treatment of phenylketonuria.
Lead Product(s): Sapropterin Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sapropterin Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Therapeutics Reports Positive Results from RLF-OD032 Study For Phenylketonuria
Details : RLF-OD032 (sapropterin dihydrochloride) is a PAH agonist small molecule drug candidate which is being evaluated for the treatment of phenylketonuria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RLF-OD032, an innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, is designed to lower blood phenylalanine in adult and pediatric PKU patients.
Lead Product(s): Sapropterin Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sapropterin Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Completes Phase in RLF-OD032 Study; Topline Results Expected October 2024
Details : RLF-OD032, an innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, is designed to lower blood phenylalanine in adult and pediatric PKU patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RLF-OD032 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): RLF-OD032,Sapropterin Hydrochloride
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RLF-OD032,Sapropterin Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects
Details : RLF-OD032 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2024

Details:
Sapropterin Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): Sapropterin Hydrochloride,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Innovent Biologics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 02, 2024

Lead Product(s) : Sapropterin Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
Details : Sapropterin Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 02, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tetrahydrobiopterin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intermittent Claudication.
Lead Product(s): Sapropterin Hydrochloride,Ascorbic Acid,L-Arginine
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Louis Messina
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 16, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sapropterin Hydrochloride,Ascorbic Acid,L-Arginine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Louis Messina
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tetrahydrobiopterin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intermittent Claudication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 16, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : SAPROPTERIN DIHYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2025-06-11
Application Number : 218797
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : SAPROPTERIN DIHYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2021-06-15
Application Number : 207685
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : SAPROPTERIN DIHYDROCHLORIDE
Dosage Form : POWDER;ORAL
Dosage Strength : 100MG/PACKET
Approval Date : 2021-03-30
Application Number : 209452
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : SAPROPTERIN DIHYDROCHLORIDE
Dosage Form : POWDER;ORAL
Dosage Strength : 500MG/PACKET
Approval Date : 2022-05-13
Application Number : 215798
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ZELVYSIA
Dosage Form : POWDER;ORAL
Dosage Strength : 100MG/PACKET
Approval Date : 2025-04-29
Application Number : 218645
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ZELVYSIA
Dosage Form : POWDER;ORAL
Dosage Strength : 500MG/PACKET
Approval Date : 2025-04-29
Application Number : 218645
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : SAPROPTERIN DIHYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2025-06-09
Application Number : 216797
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : KUVAN
Dosage Form : POWDER;ORAL
Dosage Strength : 500MG/PACKET
Approval Date : 2015-10-27
Application Number : 205065
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

Brand Name : SAPROPTERIN DIHYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2019-05-10
Application Number : 207200
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Brand Name : SAPROPTERIN DIHYDROCHLORIDE
Dosage Form : POWDER;ORAL
Dosage Strength : 100MG/PACKET
Approval Date : 2025-09-03
Application Number : 216432
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
48
PharmaCompass offers a list of Sapropterin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sapropterin Hydrochloride manufacturer or Sapropterin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sapropterin Hydrochloride manufacturer or Sapropterin Hydrochloride supplier.
PharmaCompass also assists you with knowing the Sapropterin Hydrochloride API Price utilized in the formulation of products. Sapropterin Hydrochloride API Price is not always fixed or binding as the Sapropterin Hydrochloride Price is obtained through a variety of data sources. The Sapropterin Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sapropterin Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sapropterin Hydrochloride, including repackagers and relabelers. The FDA regulates Sapropterin Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sapropterin Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sapropterin Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sapropterin Hydrochloride supplier is an individual or a company that provides Sapropterin Hydrochloride active pharmaceutical ingredient (API) or Sapropterin Hydrochloride finished formulations upon request. The Sapropterin Hydrochloride suppliers may include Sapropterin Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Sapropterin Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sapropterin Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Sapropterin Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Sapropterin Hydrochloride DMFs exist exist since differing nations have different regulations, such as Sapropterin Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sapropterin Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Sapropterin Hydrochloride USDMF includes data on Sapropterin Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sapropterin Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sapropterin Hydrochloride suppliers with USDMF on PharmaCompass.
A Sapropterin Hydrochloride written confirmation (Sapropterin Hydrochloride WC) is an official document issued by a regulatory agency to a Sapropterin Hydrochloride manufacturer, verifying that the manufacturing facility of a Sapropterin Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sapropterin Hydrochloride APIs or Sapropterin Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Sapropterin Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Sapropterin Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sapropterin Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sapropterin Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sapropterin Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sapropterin Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sapropterin Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sapropterin Hydrochloride suppliers with NDC on PharmaCompass.
Sapropterin Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sapropterin Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sapropterin Hydrochloride GMP manufacturer or Sapropterin Hydrochloride GMP API supplier for your needs.
A Sapropterin Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Sapropterin Hydrochloride's compliance with Sapropterin Hydrochloride specifications and serves as a tool for batch-level quality control.
Sapropterin Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Sapropterin Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sapropterin Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Sapropterin Hydrochloride EP), Sapropterin Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sapropterin Hydrochloride USP).